JP2024542879A5 - - Google Patents
Info
- Publication number
- JP2024542879A5 JP2024542879A5 JP2024524389A JP2024524389A JP2024542879A5 JP 2024542879 A5 JP2024542879 A5 JP 2024542879A5 JP 2024524389 A JP2024524389 A JP 2024524389A JP 2024524389 A JP2024524389 A JP 2024524389A JP 2024542879 A5 JP2024542879 A5 JP 2024542879A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- heavy chain
- amino acid
- binding site
- tgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2029844 | 2021-11-19 | ||
| NL2029844 | 2021-11-19 | ||
| PCT/EP2022/082377 WO2023089083A1 (en) | 2021-11-19 | 2022-11-18 | Multispecific binding moieties comprising pd-1 and tgf-brii binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542879A JP2024542879A (ja) | 2024-11-18 |
| JP2024542879A5 true JP2024542879A5 (https=) | 2025-03-11 |
Family
ID=80625531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524389A Pending JP2024542879A (ja) | 2021-11-19 | 2022-11-18 | Ｐｄ－１およびｔｇｆ－ｂｒｉｉ結合ドメインを含む多重特異性結合部位 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230159645A1 (https=) |
| EP (1) | EP4433505A1 (https=) |
| JP (1) | JP2024542879A (https=) |
| KR (1) | KR20240101664A9 (https=) |
| CN (2) | CN118265725A (https=) |
| AR (1) | AR127714A1 (https=) |
| AU (1) | AU2022389596A1 (https=) |
| CA (1) | CA3231649A1 (https=) |
| CL (1) | CL2024001410A1 (https=) |
| CO (1) | CO2024006325A2 (https=) |
| CR (1) | CR20240201A (https=) |
| EC (1) | ECSP24039278A (https=) |
| IL (1) | IL312214A (https=) |
| MX (1) | MX2024006018A (https=) |
| PE (1) | PE20241477A1 (https=) |
| TW (1) | TW202328180A (https=) |
| UY (1) | UY40028A (https=) |
| WO (1) | WO2023089083A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240343805A1 (en) * | 2023-04-14 | 2024-10-17 | Incyte Corporation | USE OF AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODY |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| WO2018129331A1 (en) * | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
| MX2020000055A (es) * | 2017-07-06 | 2020-08-06 | Merus Nv | Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3). |
| AU2018296067B2 (en) * | 2017-07-06 | 2021-06-10 | Merus B.V. | Binding molecules that modulate a biological activity expressed by a cell |
| CN116199780A (zh) * | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| US20220144956A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII |
-
2022
- 2022-11-18 PE PE2024001077A patent/PE20241477A1/es unknown
- 2022-11-18 CA CA3231649A patent/CA3231649A1/en active Pending
- 2022-11-18 EP EP22818694.6A patent/EP4433505A1/en active Pending
- 2022-11-18 MX MX2024006018A patent/MX2024006018A/es unknown
- 2022-11-18 CN CN202280076849.XA patent/CN118265725A/zh active Pending
- 2022-11-18 WO PCT/EP2022/082377 patent/WO2023089083A1/en not_active Ceased
- 2022-11-18 CR CR20240201A patent/CR20240201A/es unknown
- 2022-11-18 JP JP2024524389A patent/JP2024542879A/ja active Pending
- 2022-11-18 IL IL312214A patent/IL312214A/en unknown
- 2022-11-18 KR KR1020247019354A patent/KR20240101664A9/ko active Pending
- 2022-11-18 AR ARP220103179A patent/AR127714A1/es unknown
- 2022-11-18 CN CN202411831660.4A patent/CN119613560A/zh active Pending
- 2022-11-18 US US18/056,907 patent/US20230159645A1/en active Pending
- 2022-11-18 UY UY0001040028A patent/UY40028A/es unknown
- 2022-11-18 TW TW111144080A patent/TW202328180A/zh unknown
- 2022-11-18 AU AU2022389596A patent/AU2022389596A1/en active Pending
-
2024
- 2024-05-10 CL CL2024001410A patent/CL2024001410A1/es unknown
- 2024-05-17 CO CONC2024/0006325A patent/CO2024006325A2/es unknown
- 2024-05-21 EC ECSENADI202439278A patent/ECSP24039278A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7330228B2 (ja) | 抗ｃｄ３抗体、ｃｄ３及びｃｄ２０に結合する二重特異性抗原結合分子、並びにそれらの使用 | |
| CN108752476B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| ES2954153T3 (es) | Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer | |
| JP2021527431A5 (https=) | ||
| CN109563170B (zh) | 抗gitr抗体及其用途 | |
| CN104684552B (zh) | 组合及其用途 | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| CN110050000A (zh) | 含有TGF-β受体的融合蛋白及其医药用途 | |
| US20220340673A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| JP2020528750A5 (https=) | ||
| IL318482A (en) | Pd-1 inhibitor for use in a method of treating skin cancer | |
| JP2018534933A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2021528423A5 (https=) | ||
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP2022512750A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JP2020522280A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| JP2022520455A (ja) | ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞 | |
| JP2023518153A5 (https=) | ||
| CA3219336A1 (en) | Uses of anti-icos antibodies | |
| JP2023522630A (ja) | 抗ｆｌｔ３抗体及び組成物 |